

EUR Research Information Portal

Power, legitimacy and urgency

Published in:
Health Policy

Publication status and date:
Published: 01/08/2021

DOI (link to publisher):
[10.1016/j.healthpol.2021.05.002](https://doi.org/10.1016/j.healthpol.2021.05.002)

Document Version
Other version

Document License/Available under:
CC BY

Citation for the published version (APA):

van Dijk, T., van der Scheer, W., & Janssen, R. (2021). Power, legitimacy and urgency: Unravelling the relationship between Dutch healthcare organisations and their financial stakeholders. *Health Policy*, 125(8), 1077-1084.
<https://doi.org/10.1016/j.healthpol.2021.05.002>

[Link to publication on the EUR Research Information Portal](#)

Terms and Conditions of Use

Except as permitted by the applicable copyright law, you may not reproduce or make this material available to any third party without the prior written permission from the copyright holder(s). Copyright law allows the following uses of this material without prior permission:

- you may download, save and print a copy of this material for your personal use only;
- you may share the EUR portal link to this material.

In case the material is published with an open access license (e.g. a Creative Commons (CC) license), other uses may be allowed. Please check the terms and conditions of the specific license.

Take-down policy

If you believe that this material infringes your copyright and/or any other intellectual property rights, you may request its removal by contacting us at the following email address: openaccess.library@eur.nl. Please provide us with all the relevant information, including the reasons why you believe any of your rights have been infringed. In case of a legitimate complaint, we will make the material inaccessible and/or remove it from the website.



ELSEVIER

Contents lists available at ScienceDirect

Health policy

journal homepage: www.elsevier.com/locate/healthpol

Power, legitimacy and urgency: Unravelling the relationship between Dutch healthcare organisations and their financial stakeholders



T.S. (Tessa) van Dijk^{a,*}, W.K. (Wilma) van der Scheer^b, R.T.J.M. (Richard) Janssen^{a,c}

^a Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, the Netherlands

^b Erasmus Centre for Healthcare Management, Erasmus University Rotterdam, Rotterdam, the Netherlands

^c Tranzo, Tilburg School of Social and Behavioral Sciences, Tilburg University, Tilburg, the Netherlands

ARTICLE INFO

Article history:

Received 29 October 2020

Revised 6 May 2021

Accepted 10 May 2021

ABSTRACT

Healthcare organisations rely on their financial stakeholders for capital to invest in state-of-the-art buildings, equipment, innovation and the delivery of healthcare services. Nevertheless, relations between healthcare organisations and their financial stakeholders have not been well studied. Here, we studied the relations between Dutch healthcare organisations and two of their main financial stakeholders (banks and health insurers) against the backdrop of system reforms and the financial crisis. We conducted a survey of healthcare executives to evaluate their relations with banks and health insurers in terms of power, legitimacy and urgency. These three attributes are based on the salience model of Mitchel, Agle and Wood (1997). We further tested for differences in power, legitimacy and urgency across organisational sector and size. The results showed that healthcare organisations value banks as legitimate stakeholders with a well-demarcated influence and a clear-cut function. The relationship with health insurers is more complex. Healthcare organisations experience considerable influence from health insurers but question the legitimacy of their claims. Since health insurers play a crucial role in the Dutch healthcare system, these findings question the workability of the relationship between healthcare organisations and health insurers and the position of health insurers in the overall healthcare sector. Our results are relevant to countries with public-private health systems and contribute to the development of the salience model by showing the individual value of stakeholder attributes and the relevance of context.

© 2021 The Authors. Published by Elsevier B.V.

This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>)

1. Introduction

Financial stakeholders such as health insurers, governments, other third-party payers and capital providers are crucial partners for healthcare organisations. Their commitment to healthcare organisations provides financial stability and guarantees the continued existence of the organisation and the continued delivery of healthcare services. Financial stakeholders also provide opportunities for building, exploiting and renovating healthcare facilities, as well as funding medical equipment and large innovation projects. They can also influence the course and strategy of organisations through contracts and purchasing conditions. In this paper, we distinguish two types of financial stakeholders: those that purchase healthcare services and act as third-party payers and those that

provide long-term capital (e.g., private parties, banks and public-private partnerships).

Over the last decade, the dependence between healthcare organisations and financial stakeholders in many Western European countries has become more complex and diffuse because of (1) health policy changes, which have encouraged competition in healthcare, and (2) the 2007 financial crisis, which has influenced how financial stakeholders (and indirectly healthcare organisations) perceive risk. The health policy changes that occurred in the early 2000s created competition between providers of care and health insurers [1,2]. Governments implemented ‘business-like’ and ‘market-oriented’ models that placed more focus on performance indicators, accountability and control systems, and risk management in the healthcare sector [3,4]. The healthcare organisations’ financial affairs and relationships with financial stakeholders became an important focal point for all concerned in the healthcare sector.

In the years following the 2007 financial crisis, European healthcare organisations encountered difficulties gaining access to

* Corresponding author at: Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Burgemeester Oudlaan 50, 3000 DR Rotterdam, the Netherlands.

E-mail address: vandijk@eshpm.eur.nl (T.S. van Dijk).

capital since capital expenditure is affected by financial crises [5,6]. Governments adopted austerity policies aimed at reducing healthcare budgets [7–9]. Institutions such as banks and (health) insurers faced stricter capital regulations from international and European supervising authorities. The Basel III regulation for banks and Solvency II regulation for (health) insurers influenced the conditions under which capital was provided, creating stringent loan conditions for healthcare organisations and shifting the focus of both banks and health insurers towards risk management [10,11]. These developments, derived from the financial crisis, created obstacles to getting capital and affected financial stakeholders' perceptions of healthcare organisations.

In light of these developments, role perceptions have changed and the relations between healthcare organisations and financial stakeholders have reshaped and redeveloped. A deeper understanding of the dynamics of these complex relations is necessary to revisit roles, interdependencies and ways of collaborating. Changing relations between healthcare organisations and their financial stakeholders have not been well studied, despite their importance for the functioning of individual healthcare organisations and the healthcare system as a whole. To address this gap, we have used stakeholder theory, particularly the salience model developed by Mitchell, Agle and Wood [12], to disentangle the relations between healthcare organisations and their financial stakeholders. This model enables us to analyse how executives of healthcare organisations value and prioritise stakeholders based on three attributes: power, legitimacy and urgency. Although the salience model intends to identify all stakeholders and then compare them to their relative salience, we have followed the approach of Magness [13] and apply the model to two types of stakeholders.

Based on the relevance of financial stakeholders for healthcare organisations and the salience model, our research question was: How do healthcare organisations value their financial stakeholders in terms of power, legitimacy and urgency and what does that value tell us about their mutual dependence? We also discuss how this affects the functioning of the healthcare system. We investigated Dutch healthcare organisations that were subjected to healthcare reforms towards managed competition in 2006 and to the consequences of the 2007 financial crisis. We especially focus on their relations with two financial stakeholders: health insurers as purchasers of care and banks as providers of capital.

In this paper, we first explain the setting and tasks of Dutch banks, health insurers and healthcare organisations. Then we provide our theoretical framework, which elaborates on the salience model. In the methods section, we describe our survey of healthcare executives after which we present our results. Finally, we conclude and discuss the implications of our work.

2. Setting the stage: The role of financial stakeholders in Dutch healthcare

This section explains the role of banks and health insurers in Dutch healthcare, and the shifting dependencies between banks, health insurers and healthcare organisations. An essential difference between these financial stakeholders is that banks take on a more distant role from healthcare organisations than health insurers, who have a legally assigned role within the sector, do.

Banks

In the Netherlands, the banking sector provides both long-term loans and short-term credit to healthcare organisations to meet capital needs. Long-term loans are mainly used to finance real estate, renovations to buildings and facilities and to fund innovation projects and programs for new equipment (e.g., IT, medical). Short-term credit is used to pay daily expenses, wages and suppliers.

Five banks are involved in the Dutch healthcare sector; these are either commercial banks (ABN AMRO Group, ING Bank, Rabobank) or public sector banks (BNG Bank and NWB Bank). The healthcare sector comprises about 5% of the total loans provided by Dutch monetary financial institutions [14].

Since the introduction of managed competition in 2006 and the deregulation of governmental healthcare real-estate policies in 2008, Dutch healthcare organisations are responsible for their own financial stability and real estate [15]. This break with the previous risk-free policy – which based financing of real estate on subsequent funding by the government – has considerably affected the relations between banks and healthcare organisations. It has raised barriers to accessing capital for healthcare organisations and has made the financing of healthcare real estate more uncertain and riskier for both healthcare organisations and their capital providers [16–19]. Banks have been affected by stricter regulations (Basel III) induced by the financial crisis. This affected loan conditions, making healthcare organisations increasingly reliant on their financial stakeholders [11].

Health insurers

Since the introduction of managed competition in 2006, Dutch health insurers, including former public sickness funds and private insurers, consolidated into 23 competing health insurers that operate under ten concerns (2018). The four largest insurance concerns (Achmea, VGZ, CZ and Menzis) have a total market share of 86.5% [20]. Dutch health insurers operate in managed competition in two markets: the health insurance market and the health purchasing market [15]. In the health insurance market, health insurers offer annual health plans to Dutch citizens, who are obliged to select one. In the health purchasing market, health insurers annually negotiate on price, quantity and quality of services with healthcare providers [21]. In practice, these markets are interrelated; they depend on each other as the health plans offered to citizens are based on the negotiations for healthcare services.

Contracting healthcare services is one of the main tasks of health insurers. Health insurers contract healthcare services included in the Health Insurance Act (*Zvw*). In practice, this means that health insurers contract all services provided in hospital care, mental healthcare and primary care and some services in nursing care, homecare and well-being (NHW), and disability care. This last group of healthcare organisations also closes contracts with regional procurement offices and municipalities for other services. The contracts with health insurers only entail a smaller part of their total revenue.

The contracting process is crucial for health insurers to fulfil their legal obligation to provide healthcare for the insured (*zorgplicht*). However, this can be a stringent process. Not only do health insurers find it difficult to negotiate on quality of care [22], there are also powerful bargaining positions at play that hamper the finalisation of contracts and prolong the process [23,24]. This already indicates a complex relation between health insurers and healthcare organisations.

3. Theoretical framework: Stakeholder theory and the salience model

Clarkson defines stakeholders as “voluntary and involuntary risk bearers” [25]. Both banks and health insurers place voluntary stakes and resources in healthcare organisations, whose activities put them at risk. For banks, the stakes and resources at risk are capital investments and short-term credit availability. For health insurers, the stakes and resources at risk concern outsourcing their legal responsibility to provide care for the insured by contracting healthcare services.




Fig. 1. Salience model as proposed by Mitchell, Agle and Wood (1997).

To better understand the relations between healthcare organisations and banks and between healthcare organisations and health insurers, we use the salience model developed by Mitchell, Agle and Wood [12] (Fig. 1). This model has two functions: it identifies and values stakeholders and describes how salient managers are to these stakeholders. Mitchell et al. define salience as “the degree to which managers give priority to competing stakeholder claims” (p. 854) [12]. Salience has three essential stakeholder attributes: power, legitimacy and urgency. To determine overall salience, managers rate these three attributes for each stakeholder. Thus, besides offering a typology of stakeholders, the model reveals the power, legitimacy and urgency of the stakeholder–manager relationship. Combined, the stakeholder attributes represent different types of stakeholders depending on the presence of either one, two, or three attributes (Fig. 1).

Mitchell et al. defined the three stakeholder attributes as follows (p. 869) [12]: power “as a relationship among social actors in which one social actor (A) can get another social actor (B) to do something that B would not have done otherwise”; legitimacy “as a generalised perception or assumption that the actions of an entity are desirable, proper, or appropriate in some socially constructed system of norms, values, beliefs and definitions” [26]; and urgency “as the degree to which stakeholder claims call for immediate attention.” For the power attribute, the overall role of the stakeholder is emphasised, while for legitimacy and urgency the focus is on the actions and claims of that specific stakeholder [26,27]. The main idea behind the model is that the more attributes a stakeholder can employ, the more salient managers will be towards that stakeholder. Over the years, several studies have confirmed the reliability of the model [27–37].

However, there is also criticism. The two main criticisms relevant to this study involve the discrepancy between the method to calculate the degree of stakeholder attributes (on a continuum) and the stakeholder typology (binary), and the lack of context included in the model. The first criticism [26,38] relates to the discrepancy between a model that assumes attributes to be either present or absent and measuring them on a Likert scale continuum [28]. We argue that interpreting stakeholder attributes and typology involves normative judgements, whether a Likert scale or a threshold is used. This is, for example, reflected in the names assigned to the different types of stakeholders (Fig. 1). Results should be interpreted in relation to the context that stakeholders operate in and should be relative to all stakeholders. Therefore, we adopt a

rather flexible interpretation of stakeholder typology in contrast to some other authors.

The above argument aligns with the second criticism on the model: its lack of context [26]. Mitchell et al. acknowledged that stakeholder relationships are dynamic, can change over time and can be different in certain situations [12]. However, they do not incorporate this in their model, thereby possibly overlooking important aspects of the relationship between managers and stakeholders. Some authors have tried to incorporate context [28,34,39,40] with no or limited success. We attempt to incorporate context here by looking for differences in outcomes across sectors and in size of the organisation. We added questions on the influence of stakeholders on certain governance areas and interpreted our results in the context of stakeholder roles. This partly resolves the absence of context in the salience model and explains why certain attributes are valued lower or higher than others. Accordingly, we do not consider stakeholder attributes as static and fixed, but rather as a reflection of the institutional context.

To our knowledge, the model has not been applied in the healthcare setting before. It provides a new point of view in healthcare research, taking the perspective of healthcare organisations in their relations with vital financial stakeholders, thereby enabling us to better understand this relation. This research also further develops the salience model. Although management literature on the model has focused on salience, we show that its three attributes are informative and insightful both individually and together. We apply the stakeholder attributes in the broadest sense, using them to gain a deeper understanding of the relations between healthcare organisations, banks and health insurers, and thus giving insight into the dependencies between actors and the characteristics of their relations in context.

4. Material and methods

Survey questions

We conducted a survey of healthcare executives to answer the research question. The questions on stakeholder attributes were based on the operationalisation of the salience model proposed by several authors [12,28,31]. We altered the question on legitimacy as suggested by Neville et al. [26]. Other questions in the survey explicated the power attribute in terms of influence on several governance areas of the healthcare organisation. There were also general questions on respondents and their organisation. To min-

imise confusion, the bank was specified as the main bank (*huisbankier*) and the health insurer as the one with whom respondents closed the largest contract for 2018 (see Online Appendix 1 for a complete overview of the survey). Four executives from different sectors tested the survey for clarity and validity. Agle et al. demonstrated the reliability and validity of the model (p. 514) [28] and the questions they proposed and tested form the basis of our survey. We also performed a reliability tests for the composition of salience for banks (Cronbach's Alpha = 0.605¹) and health insurers (Cronbach's Alpha = .595¹). Outcomes were slightly higher when legitimacy was deleted as an attribute for salience (respectively 0.746 and 0.714).

Respondents and their organisation

Healthcare executives were chosen as the most suitable respondents to evaluate and value relations with banks and health insurers on behalf of the healthcare organisation. Executives are often in touch with both financial stakeholders. They have regular meetings with the bank on financial issues and lead the negotiations with the health insurer over healthcare services.

To reach respondents, the survey was sent out in collaboration with the Dutch Association of Healthcare Executives (NVZD) at the beginning of 2019. The NVZD is a professional association representing executives in the Dutch healthcare sector. In total, 714 members received an invitation and 308 (43%) respondents began the survey. The exact number of Dutch healthcare executives is not known. The NVZD claim that they represent two-thirds of all Dutch healthcare executives [41]².

Respondents were informed about the goal and background of the study. We excluded respondents from analysis if their organisation was not a healthcare organisation ($n = 1$), their main funder was not a bank or if they had no relations with a health insurer ($n = 6$). Some executives were only excluded from questions regarding the health insurer because they indicated that they had no contract with health insurers ($n = 31$). Ultimately, 269 (38%) respondents completed the survey.

Information on participating healthcare executives and their organisations is displayed in Online Appendix 2. A cross table of organisational sector and size can be found in Online Appendix 3. Based on the organisational size of the primary care sector, we believe that this dataset mainly contains regional GP organisations, out-of-hours cooperatives and/or care groups. Overall, characteristics of healthcare executives and their organisations are convincingly representative of the sector as they are similar to available information of the NVZD on their members [41]² and to previous studies of Dutch healthcare executives [42–44]. Therefore, results from our study population can likely be generalised to the total population of Dutch healthcare executives.

Analysis

The purpose of this research is to analyse information on the three main stakeholder attributes and possible differences across organisational sector and size. This was done in a descriptive and in-depth way, making use of SPSS and contextual information.

The three attributes were checked for outliers, but no outliers had a significant influence on the results. Legitimacy had no outliers at all, indicating that healthcare executives have a shared view regarding this attribute. Salience was calculated as the average of all attributes weighted equally. This is in line with earlier research that found a positive relation between the cumulative stakeholder attributes and salience (p. 518, 520) [28,31].

To assess possible differences in stakeholder attributes across organisational sector and size, we merged some of the categories of these variables. Size was reconstructed for a better distribution and new sector variables were created in accordance with the conventional Dutch sector classification. We then performed a one-way ANOVA and Tukey post-hoc test. The test was in line with assumptions of an approximately normal distribution, homogeneity of variances (using Levene's test and the Brown–Forsythe test if assumption of homogeneity was violated) and independence of samples.

5. Results

Stakeholder attributes

Fig. 2 shows the mean outcomes of stakeholder attributes and salience as perceived by healthcare executives.

The outcomes of the stakeholder attributes were reversed for banks and health insurers, which led to a difference in salience. For banks, power ($n = 294$; $sd=2.46$) and urgency ($n = 296$; $sd=2.47$) were perceived relatively low by healthcare executives compared with health insurers. The legitimacy ($n = 296$, $sd=1.45$) attribute of banks, however, was relatively high. The opposite was the case for health insurers, where power ($n = 253$; $sd=1.78$) and urgency ($n = 253$; $sd=2.00$) were relatively high and legitimacy ($n = 254$; $sd=1.72$) was relatively low. The overall outcome for salience showed a relative higher score for health insurers compared with banks.

The exercise of power

There is a considerable difference between banks and health insurers regarding the power attribute (4.3 vs. 7.0). To decompose this attribute and discover where influence is exercised, respondents were asked to indicate the degree of influence on certain governance areas within the organisation (Fig. 3).

Healthcare executives reported that banks mainly influenced real estate and housing ($n = 126$; 43.7%), investments ($n = 109$; 37.9%) and finance ($n = 107$; 37.2%) whereas health insurers influenced every aspect of the healthcare organisation. Notable were quality of care ($n = 125$; 49.8%), strategy ($n = 137$; 60.2%) and finance ($n = 183$; 72.9%) – where, remarkably, the perceived influence of health insurers was considerably higher than that of banks.

Stakeholder attributes across sectors and size

For each stakeholder attribute, the differences in outcomes were compared across organisational sector and size. Table 1 reports the significant differences based on one-way ANOVA and Tukey post-hoc tests. Significant differences ($p < 0.05$) for banks were found between types of healthcare organisations on the power attribute ($F(5263) = 4.395$, $p = 0.001$) and between different-sized healthcare organisations regarding the power attribute ($F(5263) = 6.518$, $p = 0.001$) and urgency attribute ($F(5263) = 4.749$, $p = 0.001$). Significant differences ($p < 0.05$) for health insurers were found between types of healthcare organisations on the power attribute ($F(5233) = 2.446$, $p = 0.035$), the legitimacy attribute ($F_{\text{asympt}} = 2.706$, $df_1=5$, $df_2 = 128.48$, $p = 0.023$) and the urgency attribute ($F_{\text{asympt}} = 4.884$, $df_1 = 5$, $df_2 = 189.931$, $p = 0.001$).

The distinction between groups across sector and size account for contextual factors that are generally overlooked by the salience model. Therefore, the results presented in Table 1 contribute to the understanding and interpretation of the stakeholder attributes. The results for banks show that smaller (EUR < 50 million) healthcare organisations experience both the influence of banks and the ability of banks to pressure claims significantly differently compared with larger (EUR > 151 million) healthcare organisations. The perceived differences for banks between primary care and hospitals,

¹ Reverse-coded for legitimacy attribute.

² Source not publicly accessible. Document is available from the corresponding author on request.




Fig. 2. Healthcare executives' perceptions of mean stakeholder attributes and salience of banks and health insurers.




Fig. 3. Healthcare executives' perceptions of the (very) high influence (%) that banks and health insurers have on governance areas in the healthcare organisation.

Table 1
Significant differences between groups for banks and health insurers.

Banks (n = 288)		Attribute	Sector and Size	Mean	Sector and Size	Mean	P-value
Sector	Power	Primary care	Hospitals	2.53	Hospitals	5.04	.001
			Mental Healthcare			4.68	.013
			Combination			4.94	.007
Size	Power	EUR < 15 million	EUR 151 – 200 million	3.55	EUR 151 – 200 million	5.44	.014
			EUR > 200 million			5.13	.012
			EUR 15 – 50 million	3.36	EUR 51 – 100 million	4.74	.040
	Urgency	EUR < 15 million	EUR 101 – 150 million			4.97	.012
			EUR 151 – 200 million			5.44	.002
			EUR > 200 million			5.13	.001
EUR 15 – 50 million	EUR 151 – 200 million	3.63	EUR 151 – 200 million	5.40	.036		
	EUR > 200 million			5.15	.025		
	EUR > 200 million	3.64	EUR 151–200 million	5.40	.025		
		EUR > 200 million			5.15	.014	
Health insurers (n = 251)		Attribute	Sector	Mean	Sector	Mean	P-value
Sector	Power	Mental healthcare	7.61	Disability care	6.17	.032	
	Legitimacy	Primary care	4.58	Disability care	6.38	.007	
	Urgency	Nursing care, homecare and well-being (NHW)	Mental healthcare	6.42	Mental healthcare	7.64	.034
			Primary care			8.16	.008
	Primary care	8.16	Disability care	6.25	.019		

mental healthcare and combined healthcare organisations might be related to differences in size. The included primary care organisations all have an annual revenue below 50 million, while hospitals, mental healthcare and combined healthcare organisations have greater revenues (Online Appendix 3).

Health insurers are valued significantly differently across sectors, particularly across disability care, primary care and the mental healthcare sectors. Executives working in disability care value health insurers significantly differently than executives in mental healthcare do in terms of power, than executives in primary care do in terms of legitimacy, and than executives in NHW and primary care do in terms of urgency. Primary care experiences significantly different degrees of legitimacy and urgency than disability care and NHW do. The mental healthcare sector stood out on the power and urgency attributes.

6. Discussion

This research tried to unravel the relationship between Dutch healthcare organisations and two crucial financial stakeholders: banks and health insurers. Our use of the salience model – interpreting results by taking contextual factors into account and by contrasting two financial stakeholders – made it possible to explore the relations in depth using data from a large group of respondents. The first part of the research question focused on the healthcare executives' valuation of the relationship in terms of power, legitimacy and urgency. The results showed that healthcare executives experienced more influence by health insurers than by banks. However, the claims of banks are perceived to be more legitimate than those of health insurers, while the claims of health insurers are more pressing. The results on the salience attribute indicate that healthcare executives prioritise the claims of health insurers over the claims of banks. Furthermore, banks have a clear-cut interest in certain areas of the organisation, which makes them an unambiguous stakeholder. The influence of health insurers is more diverse and diffuse. Based on the stakeholder typology of the salience model (Fig. 1) and considering the relative outcomes and context, healthcare executives perceive banks as 'discretionary' stakeholders and health insurers as 'dangerous' stakeholders.

For the valuation of banks, organisational size is a contextual factor that matters. Banks invest more capital in larger organisations, therefore interdependencies increase and more financial risks are at stake. It is likely that banks will exercise relatively more power on larger healthcare organisations and pressure their claims accordingly, e.g., through increased monitoring.

For the valuation of health insurers, we found significant differences between sectors, indicating that sector-specific circumstances are at stake. For instance, the mental healthcare sector not only faced major reforms on the payment structure but also dealt with ongoing struggles regarding reimbursement practices [11]. Regional GP organisations, out-of-hours cooperatives and care groups employ GPs who are open about their dissatisfaction with health insurers, which is in line with our finding on significantly lower legitimacy [24]. In regard to other sectors, differences might be related to the share of health insurer contracts on the total revenue of the organisations.

The second part of the research question aimed to determine perceived interdependencies between healthcare organisations and financial stakeholders in relation to the overall healthcare system. Several implications can be drawn from our results, starting with the bank and followed by the health insurer. The outcomes suggest that banks are accepted, credible and appreciated stakeholders. Despite the increased dependency and complexity of the relationship after healthcare reforms and regulations (Basel III) were introduced, banks have been able to secure an acknowledged posi-

tion. This might be explained by their somewhat distant role in the sector and their single focus on financial governance areas. Banks also possess a thorough knowledge of financial issues that is often not present in healthcare organisations and they barely mingle with other strategic domains. The role, interests and expertise of banks are clear and demarcated, and their authority seems undisputed.

The position of health insurers in relation to healthcare organisations proved to be more complex. Health insurers have a legal obligation to negotiate the price, quantity and quality of healthcare services with healthcare organisations. In line with this, our study shows that health insurers exert a great deal of influence on healthcare organisations that covers both financial aspects and substantive topics (e.g. quality of care). However, healthcare executives are questioning the desirability and appropriateness of this legal obligation. A lack of legitimacy will in most cases obstruct interactions between health insurers and healthcare organisations – as suggested by others [22,23,24]. Altogether, such impediments make negotiations an unsatisfying process from the perspective of healthcare organisations.

Although this study focuses on healthcare systems in the Netherlands, these outcomes are relevant for other countries as well, especially those with healthcare systems that include private investors, public–private partnerships and health insurers. In an international context, our study shows that one should be careful in assuming a workable and satisfied relationship between healthcare organisations and their financial stakeholders. It is possible that there are underlying obstacles in place that impede a good relationship, which in turn affect the practices of healthcare organisations. In Western Europe, the cost and demand for healthcare is increasing, and dependencies between healthcare organisations and their financial stakeholders will increase simultaneously. Raising awareness of relations between financial stakeholders and healthcare organisations and acknowledging the claims and roles of the other party are the minimum requirements for finding solutions. Good relations will prove equally important.

Strengths & limitations

A strength of this study is that the salience model has not been applied to the healthcare setting before. This study has added to the salience model by showing that all three attributes contain relevant in-depth information in themselves and are therefore individually important. This research has also shown that context and setting are important aspects when interpreting the results of the salience model. We also argued that stakeholder typology requires a normative interpretation of stakeholder attributes and what type of stakeholder is faced. Future research should take these points into consideration.

Our study has limitations, especially concerning the survey. It might be possible that multiple executives working for the same organisation are members of the NVZD and have filled in the survey. We believe that this is not very plausible because executives are more likely to consult with one of their board members on who completes a time-consuming survey. Another difficulty might be that our use of legitimacy as 'desirable and appropriate' contains two different aspects. We believe both terms together refer to a situation that is 'ideal' or 'should be' and are not mutually exclusive. They complement each other in the construction of legitimacy by adding a moral characteristic as proposed by Neville et al. [26]. Nevertheless, it could be wise to separate these terms in future surveys or to choose one of the two terms. Finally, additional questions might have provided more specific information on the stakeholders, such as the type of bank (i.e., public or private sector) and the share of health insurer contracts on the total annual revenue.

This research focused on the perceived value of financial stakeholders by healthcare organisations. However, it did not show how these relations work in practice and how relations are formed and maintained. Furthermore, this study focused on one perspective: that of healthcare executives as representatives of healthcare organisations. We cannot draw conclusions on how financial stakeholders value their relation with healthcare organisations. For future research, it would be interesting to involve more perspectives and to study how relations between healthcare organisations and health insurers can move on to a sustainable and fruitful partnership, since much depends on it.

7. Conclusion & recommendations

Given the mutual dependency between healthcare organisations and their financial stakeholders, it is important to research the complexity of their relationship. The position and role of banks, health insurers and healthcare organisations in the Dutch healthcare system are crucial for the quality of the collaboration and for finding a balance between experienced power, legitimacy and urgency.

The results show that the role of health insurers in the Netherlands is under pressure. Despite their crucial role in the system, it is questioned whether insurers have sufficient support among healthcare executives. Two recent studies [45,46] have illustrated the danger of low trust in health insurers from the perspective of the insured. Here we show a different threat: the workability of the healthcare system when healthcare executives do not accept health insurers as parties with a legitimate claim. This highlights a broader legitimacy issue for health insurers to resolve on both the health purchasing market and the health insurance market.

To transcend this issue, the discussion should move beyond the question of whether health insurers fulfil their legal task correctly. Instead, the discussion should focus on the quality of the collaboration between health insurers and healthcare organisations. In everyday practice, both parties need to come to agreements. This proves difficult in a situation where at least one party does not accept the claims and actions of the other. It is therefore important that healthcare organisations and health insurers come to a shared understanding on their future collaboration and strategy based on a long-term shared vision. We already see some examples of this in the Netherlands, where several health insurers and healthcare organisations have signed long-term contracts. These contracts include agreements for future developments based on common goals. Another Dutch example, in which long-term partnerships are formed, is the development of regional visions. Here, health insurers and healthcare providers work together to make healthcare future-proof for certain challenging regions. It is plausible that such initiatives lead to a better collaboration and valuation between health insurers and healthcare organisations. But, most importantly, healthcare organisations and health insurers should develop trust, mutual appreciation and a willingness to cooperate to make healthcare work.

Source of funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Declaration of Competing Interest

None.

Acknowledgements

The authors would like to thank two groups for their useful insights and constructive feedback on earlier drafts of the paper:

members of the Health Care Governance group at the Erasmus University Rotterdam at the discussion session on 3 February 2020 and the attendees of the panel 'Governance, politics and implementation in local welfare and health politics' at the NIG Annual Conference on 8 November 2019 in Amsterdam. We would also like to express our gratitude to everyone who provided us with helpful advice and feedback on the survey.

We are especially grateful to our respondents, who took the time to fill out the survey, and the NVZD who made it possible to contact healthcare executives through their member base. Finally, we are grateful to the anonymous reviewers for their valuable comments and suggestions.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.healthpol.2021.05.002.

References

- [1] Cutler DM. Equality, efficiency, and market fundamentals: the dynamics of international medical care reform. *J Econ Lit* 2002;40(3):881–906.
- [2] Maarse H. The privatization of health care in Europe: an eight-country analysis. *J Health Polit, Policy Law* 2006;31(5):981–1014.
- [3] van Erp J, Wallenburg I, Bal RA. Performance regulation in a networked healthcare system: from cosmetic to institutionalized compliance. *Public Adm* 2018;98(1):46–61.
- [4] Simonet D. The new public management theory and the reform of European health care systems: an international comparative perspective. *Int J Public Administration* 2011;34(12):815–26.
- [5] HOPE The crisis, hospitals and healthcare. Brussels: HOPE Publications; 2011.
- [6] OECD/EU Health at a glance. Europe 2018: state of health in the EU cycle. Paris: OECD Publishing; 2018.
- [7] Quaglio G, Karapiperis T, van Woensel L, Arnold E, McDaid D. Austerity and health in Europe. *Health Policy (New York)* 2013;113:13–19.
- [8] Mladovsky P, Srivastava D, Cyclus J, Karanikolos M, Evetovits T, Thomson S, McKee M. Health policy responses to the financial crisis in Europe. Copenhagen: WHO; 2012.
- [9] Stadhouers N, Kruse F, Tanke M, Koolman X, Jeurissen P. Effective healthcare cost-containment policies. A systematic review. *Health Policy (New York)* 2019;123:71–9.
- [10] Colla P, Hellowell M, Vecchi V, Gatti S. Determinants of the cost of capital for privately financed hospital projects in the UK. *Health Policy (New York)* 2015;119:1442–9.
- [11] Janssen RTJM. Uncertain times. Ambidextrous management in healthcare. (Inaugural lecture). Rotterdam: Erasmus University Rotterdam; 2017.
- [12] Mitchell RK, Agle BR, Wood DJ. Toward a theory of stakeholder identification and salience: defining the principle of who and what really counts. *Acad Manage Rev* 1997;22(4):853–86.
- [13] Magness V. Who are the stakeholders now? An empirical examination of the Mitchell, Agle and Wood theory of stakeholder salience. *J Bus Ethics* 2008;83:177–92.
- [14] DNB Leningen en deposito's verstrekt door MFI's aan niet-financiële bedrijven in Nederland, uitgesplitst naar bedrijfstak, gecorrigeerd voor breuken, per kwartaal [Loans and deposits provided by MFI's to non-financial companies in the Netherlands classified by sector, corrected for breaks, quarterly]; April 29, 2020. [Datafile] Available from <https://statistiek.dnb.nl/downloads/index.aspx#/details/leningen-en-deposito-s-verstrekt-door-mfi-s-aan-niet-financi-le-bedrijven-in-nederland-uitgesplitst-naar-bedrijfstak-gecorrigeerd-voor-breuken-kwartaal/dataset/>.
- [15] Enthoven AC, van den Ven WPMM. Going Dutch – Managed Competition Health Insurance in the Netherlands. *N Engl J Med* 2007;357(24):2421–3.
- [16] Huisman E, Appel-Meulenbroek R, Kort H, Arentze T. Identifying the criteria for corporate real estate decisions through the laddering technique: an analysis of care organisations in The Netherlands. *J Corporate Real Estate* 2020 Vol. ahead-of-print. No. ahead-of-print.
- [17] Kroneman M, Boerma W, van den Berg M, Groenwegen P, de Jong J, van Ginneken E. The Netherlands: health system review. *Health Syst Transit* 2016;18(2):1–239.
- [18] Van der Voordt TJM. Adding value by health care real estate: parameters, priorities and interventions. *J Corporate Real Estate* 2016;18(2):145–59.
- [19] Van de Zwart J, van der Voordt T, de Jonge H. Private Investment in Hospitals: a Comparison of Three Healthcare Systems and Possible Implications for Real Estate Strategies. *Research* 2010;3(3):70–86.
- [20] NZa. Monitor Zorgverzekeringen 2018 [Monitor Health Insurances 2018]. Utrecht: Nederlandse zorgautoriteit (NZa); 2016.
- [21] Maarse H, Jeurissen P, Ruwaard D. Results of the market-oriented reform in the Netherlands: a review. *Health Econ* 2016;11:161–78 Policy and Law..
- [22] Stolper KCF, Boonen LHHM, Schut FT, Varkevisser M. Managed competition in the Netherlands: do insurers have incentives to steer on quality? *Health Policy (New York)* 2019;123:293–9.

- [23] Halbersma RS, Mikkers MC, Motchenkova E, Seinen I. Market structure and hospital-insurer bargaining in the Netherlands. *Eur J Health Econ* 2011;12:589–603.
- [24] Schut FT, Varkevisser M. Competition policy for health care provision in the Netherlands. *Health Policy (New York)* 2017;121:126–33.
- [25] Clarkson MBE. A risk-based model of stakeholder theory. In: *Proceedings of the Second Toronto Conference on Stakeholder Theory*; 1994. Toronto, Canada. Toronto: University of Toronto; 1994.
- [26] Neville BA, Bell SJ, Whitwell GJ. Stakeholder salience revisited: refining, redefining, and refueling an underdeveloped conceptual tool. *J Bus Ethics* 2011;102(3):357–78.
- [27] Eesley C, Lenox MJ. Firm responses to secondary stakeholder action. *Strat Manage J* 2006;27(8):765–81.
- [28] Agle BR, Mitchell RK, Sonnefeld JA. Who matters to CEOs? An investigation of stakeholder attributes and salience, corporate performance, and CEO values. *Acad Manage J* 1999;42(5):507–25 1999.
- [29] Gago RF, Antoliñ MN. Stakeholder salience in corporate environmental strategy. *Corporate Governance* 2004;4(3):65–76.
- [30] Gifford EJM. Effective shareholder engagement: the factors that contribute to shareholder salience. *J Bus Ethics* 2010;92(1):79–97.
- [31] Guerri M, Shani AB. Moving toward stakeholder-based HRM: a perspective of Italian HR managers. *Int J Human Resource Manage* 2013;24(6):1130–50.
- [32] Knox S, Gruar C. The application of stakeholder theory to relationship marketing strategy development in a non-profit organization. *J Bus Ethics* 2007;75(2):115–35.
- [33] Magness V. Who are the stakeholders now? An empirical examination of the Mitchell, Agle, and Wood theory of stakeholder salience. *J Bus Ethics* 2008;83(2):177–92.
- [34] Parent MM, Deephouse DL. A case study of stakeholder identification and prioritization by managers. *J Bus Ethics* 2007;75(1):1–23.
- [35] Ryan LV, Schneider M. Institutional investor power and heterogeneity: implications for agency and stakeholder theories. *Bus Soc* 2003;42(4):398–429.
- [36] Su Z, Xie E, Li Y. Organizational slack and firm performance during institutional transitions. *Asia Pacific J Manage* 2009;26(1):76–91.
- [37] Thijssens T, Bollen L, Hassink H. Secondary stakeholder influence on CSR disclosure: an application of stakeholder salience theory. *Jo Bus Ethics* 2015;132(4):873–91.
- [38] Zimmerman MA, Zeitz GJ. Beyond survival: achieving new venture growth by building legitimacy. *Acad Manage Rev* 2002;27:414–31.
- [39] Jones TM, Felps W, Bigley GA. Ethical theory and stakeholder related decisions: the role of stakeholder culture. *Acad Manage Rev* 2007;32(1):137–55.
- [40] Pfarrer MD, Decelles KA, Smith KG, Taylor MS. After the fall: reintegrating the corrupt organization. *Acad Manage Rev* 2008;33(3):730–49.
- [41] N.V.Z.D. Jaarverslag 2019 [Annual Report 2019]. Zeist: NVZD; 2019.
- [42] Bijloos S, van der Scheer WK, van Veen-Berkx L. Bestuurders in beeld. vijftien jaar onderzoek naar het besturen van zorgorganisaties [The image of executives. fifteen years of research into the governing of healthcare organisations]. Utrecht: De Tijdstroom; 2017.
- [43] Van der Scheer WK, Onder Zorgbestuurders. Omgaan met bestuurlijke ambiguïteit in de zorg [Among healthcare executives. dealing with managerial ambiguity in healthcare]. Amsterdam: Reed Business Education; 2013.
- [44] Postma J, Roos AF. Why healthcare providers merge. *Health Economics. Policy Law* 2016;11:121–40.
- [45] Groenewegen PP, Hansen J, de Jong JD. Trust in times of health reform. *Health Policy (New York)* 2019;123:281–7.
- [46] Maarse H, Jeurissen P. Low institutional trust in health insurers in Dutch health care. *Health Policy (New York)* 2019;123:288–92.